Workflow
Artelo Biosciences Announces Closing of $2.0 Million Public Offering
Globenewswire· 2025-10-01 20:05
SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,335 shares of A ...
Horizon Bancorp, Inc. Announces Conference Call to Review Third Quarter Results on October 23
Globenewswire· 2025-10-01 20:05
MICHIGAN CITY, Ind., Oct. 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ GS: HBNC) -- Horizon Bancorp, Inc. (“Horizon” or the “Company”) will host a conference call at 7:30 a.m. CT on Thursday, October 23, 2025 to review its third quarter 2025 financial results. The Company’s third quarter 2025 news release will be published after markets close on Wednesday, October 22, 2025. It will be available at investor.horizonbank.com. Participants may access the live conference call on October 23, 2025 at 7:30 a.m. CT (8:30 a. ...
Alpine Income Property Trust Announces Third Quarter and Year-to-Date 2025 Transaction Activity
Globenewswire· 2025-10-01 20:05
WINTER PARK, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) today announced its investment and disposition activities for the third quarter and year-to-date 2025. Investment and Disposition Activity During the third quarter 2025, the Company completed the following transaction activity: Acquired two properties on September 30, 2025 each ground leased to Lowe’s, an investment grade tenant (rated BBB+ by S&P), for $21.1 million representing a weighted ...
Robinhood Markets, Inc. to Announce Third Quarter 2025 Results on November 5, 2025
Globenewswire· 2025-10-01 20:05
MENLO PARK, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Today, Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) announced that it will release its third quarter 2025 financial results on Wednesday, November 5, 2025, after market close. Robinhood will host a video call to discuss its results at 2:00 PM PT / 5:00 PM ET on the same day. The video call and supporting materials will be available at investors.robinhood.com. The event will also be live streamed to YouTube and X.com via Robinhood’s official chann ...
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
Globenewswire· 2025-10-01 20:05
WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that data will be presented at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in Seattle, Washington on October 22-25, ...
Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025
Globenewswire· 2025-10-01 20:05
TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, November 13, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dia ...
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
Globenewswire· 2025-10-01 20:05
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron Dr. George Paletta George Paletta, Jr., MD, MBA MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and i ...
Hubbell Incorporated Completes Acquisition of DMC Power
Globenewswire· 2025-10-01 20:05
Shelton, CT, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Hubbell Incorporated (NYSE: HUBB) (“Hubbell”) today announced that it has completed its acquisition of DMC Power, LLC (“DMC Power”) from an affiliate of Golden Gate Capital. Hubbell financed the acquisition and related transactions with net proceeds from borrowings under a new unsecured term loan facility in the aggregate principal amount of $600 million and issuances of commercial paper. DMC Power is a designer and manufacturer of connector technology systems ...
The Lovesac Company Announces Participation in Upcoming Investor Conference
Globenewswire· 2025-10-01 20:05
STAMFORD, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, announced today that the Company is scheduled to participate in the 2025 Global Consumer & Retail Conference hosted by Telsey Advisory Group in collaboration with Santander Corporate & Investment Banking on Wednesday, October 8, 2025, at 3:30 p.m. Eastern Time. The fireside chat wil ...
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
Globenewswire· 2025-10-01 20:05
Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targetin ...